LncRNA TTN‑AS1 promotes endometrial cancer by sponging miR‑376a‑3p. 2020

Longde Shen, and Yinyin Wu, and Ailu Li, and Lichun Li, and Longyuan Shen, and Qiuxia Jiang, and Qiuxia Li, and Zhifen Wu, and Liji Yu, and Xiaohong Zhang
Department of Gynecology and Obstetrics, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian 362000, P.R. China.

Increasing research has demonstrated that lncRNAs participate in the development of multiple cancer types. However, the role of TTN‑AS1 in endometrial cancer (EC) remains unknown. The present study aimed to explore the function of titin‑antisense RNA1 (TTN‑AS1) in EC progression and the underlying mechanisms. qRT‑PCR was performed to assess the TTN‑AS1 expression patterns in EC tissues and cell lines. Loss of function experiments were carried out to estimate the effects of TTN‑AS1 on EC cell proliferation, migration and invasion. To reveal the underlying mechanisms, informatics tools were used to predict the targets. Rescue experiments were performed to investigate the TTN‑AS1‑regulated miR‑376a‑3p/pumilio homolog 2 (PUM2) axis involved. The results of the present study revealed that TTN‑AS1 was highly expressed in both EC tissues and cell lines, and TTN‑AS1 knockdown inhibited EC cell proliferation, migration and invasion. With respect to the mechanisms, miR‑376a‑3p was revealed to be targeted by TTN‑AS1, and reversed the effects on EC development induced by TTN‑AS1. In addition, PUM2 was positively regulated by TTN‑AS1, and miR‑376a‑3p mediated the regulation between them. Furtherly, in vivo experiments confirmed the results. Collectively, TTN‑AS1 enhanced EC cell proliferation and metastasis by targeting the miR‑376a‑3p/PUM2 axis, which may shed light on EC diagnosis and treatment.

UI MeSH Term Description Entries
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D016601 RNA-Binding Proteins Proteins that bind to RNA molecules. Included here are RIBONUCLEOPROTEINS and other proteins whose function is to bind specifically to RNA. Double-Stranded RNA-Binding Protein,Double-Stranded RNA-Binding Proteins,ds RNA-Binding Protein,RNA-Binding Protein,ds RNA-Binding Proteins,Double Stranded RNA Binding Protein,Double Stranded RNA Binding Proteins,Protein, Double-Stranded RNA-Binding,Protein, ds RNA-Binding,RNA Binding Protein,RNA Binding Proteins,RNA-Binding Protein, Double-Stranded,RNA-Binding Protein, ds,RNA-Binding Proteins, Double-Stranded,ds RNA Binding Protein
D016889 Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells. Cancer of Endometrium,Endometrial Cancer,Endometrial Carcinoma,Cancer of the Endometrium,Carcinoma of Endometrium,Endometrium Cancer,Neoplasms, Endometrial,Cancer, Endometrial,Cancer, Endometrium,Cancers, Endometrial,Cancers, Endometrium,Carcinoma, Endometrial,Carcinomas, Endometrial,Endometrial Cancers,Endometrial Carcinomas,Endometrial Neoplasm,Endometrium Cancers,Endometrium Carcinoma,Endometrium Carcinomas,Neoplasm, Endometrial
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D062085 RNA, Long Noncoding A class of untranslated RNA molecules that are typically greater than 200 nucleotides in length and do not code for proteins. Members of this class have been found to play roles in transcriptional regulation, post-transcriptional processing, CHROMATIN REMODELING, and in the epigenetic control of chromatin. LincRNA,RNA, Long Untranslated,LINC RNA,LincRNAs,Long Intergenic Non-Protein Coding RNA,Long Non-Coding RNA,Long Non-Protein-Coding RNA,Long Noncoding RNA,Long ncRNA,Long ncRNAs,RNA, Long Non-Translated,lncRNA,Long Intergenic Non Protein Coding RNA,Long Non Coding RNA,Long Non Protein Coding RNA,Long Non-Translated RNA,Long Untranslated RNA,Non-Coding RNA, Long,Non-Protein-Coding RNA, Long,Non-Translated RNA, Long,Noncoding RNA, Long,RNA, Long Non Translated,RNA, Long Non-Coding,RNA, Long Non-Protein-Coding,Untranslated RNA, Long,ncRNA, Long,ncRNAs, Long

Related Publications

Longde Shen, and Yinyin Wu, and Ailu Li, and Lichun Li, and Longyuan Shen, and Qiuxia Jiang, and Qiuxia Li, and Zhifen Wu, and Liji Yu, and Xiaohong Zhang
March 2020, Life sciences,
Longde Shen, and Yinyin Wu, and Ailu Li, and Lichun Li, and Longyuan Shen, and Qiuxia Jiang, and Qiuxia Li, and Zhifen Wu, and Liji Yu, and Xiaohong Zhang
September 2020, Oncology reports,
Longde Shen, and Yinyin Wu, and Ailu Li, and Lichun Li, and Longyuan Shen, and Qiuxia Jiang, and Qiuxia Li, and Zhifen Wu, and Liji Yu, and Xiaohong Zhang
August 2020, Biological chemistry,
Longde Shen, and Yinyin Wu, and Ailu Li, and Lichun Li, and Longyuan Shen, and Qiuxia Jiang, and Qiuxia Li, and Zhifen Wu, and Liji Yu, and Xiaohong Zhang
May 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Longde Shen, and Yinyin Wu, and Ailu Li, and Lichun Li, and Longyuan Shen, and Qiuxia Jiang, and Qiuxia Li, and Zhifen Wu, and Liji Yu, and Xiaohong Zhang
July 2020, Aging,
Longde Shen, and Yinyin Wu, and Ailu Li, and Lichun Li, and Longyuan Shen, and Qiuxia Jiang, and Qiuxia Li, and Zhifen Wu, and Liji Yu, and Xiaohong Zhang
May 2024, Cell division,
Longde Shen, and Yinyin Wu, and Ailu Li, and Lichun Li, and Longyuan Shen, and Qiuxia Jiang, and Qiuxia Li, and Zhifen Wu, and Liji Yu, and Xiaohong Zhang
January 2021, Frontiers in oncology,
Longde Shen, and Yinyin Wu, and Ailu Li, and Lichun Li, and Longyuan Shen, and Qiuxia Jiang, and Qiuxia Li, and Zhifen Wu, and Liji Yu, and Xiaohong Zhang
August 2022, Anti-cancer drugs,
Longde Shen, and Yinyin Wu, and Ailu Li, and Lichun Li, and Longyuan Shen, and Qiuxia Jiang, and Qiuxia Li, and Zhifen Wu, and Liji Yu, and Xiaohong Zhang
January 2021, Journal of immunology research,
Longde Shen, and Yinyin Wu, and Ailu Li, and Lichun Li, and Longyuan Shen, and Qiuxia Jiang, and Qiuxia Li, and Zhifen Wu, and Liji Yu, and Xiaohong Zhang
January 2020, Cancer cell international,
Copied contents to your clipboard!